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Abstract
Background: Genetic variants of proteins involved in lipid metabolism may play an important role
in determining the susceptibility for complications associated with type II diabetes mellitus (T2DM).
Goal of the present study was to determine the association of cholesteryl ester transfer protein
TaqI B, D442G, and APOE Hha I polymorphisms with T2DM and its complications.
Methods: Study subjects were 136 patients and 264 healthy controls. All polymorphisms were
detected using PCR-RFLP and statistical analysis done with χ2 test and ANOVA.
Results: Although CETP TaqI B polymorphism was not associated with the T2DM, yet B1B2
genotype was significantly (p = 0.028) associated with high risk of hypertension in diabetic patients
(OR = 3.068, 95% CI 1.183–7.958). In North Indians D442G variation in CETP gene was found to
be absent. Frequency of APOE HhaI polymorphism was also not different between patients and
controls. In diabetic patients having neuropathy and retinopathy significantly different levels of total-
cholesterol [(p = 0.001) and (p = 0.029) respectively] and LDL-cholesterol [(p = 0.001) and (p =
0.001) respectively] were observed when compared to patients with T2DM only. However, lipid
levels did not show any correlation with the CETP TaqI B and APOE Hha I genetic polymorphisms.
Conclusion: CETP TaqI B and APOE HhaI polymorphism may not be associated with type II
diabetes mellitus in North Indian population, however CETP TaqI B polymorphism may be
associated with hypertension along with T2DM.
Background
Dyslipidemia is a major cardiovascular risk factor in type
II diabetes mellitus (T2DM) with coronary heart disease
being the most common cause of death. Risk relates to
raised triglycerides (TG) and decreased high density lipo-
proteins (HDL) as well as raised low density lipoproteins
(LDL). In diabetes, lipid risk thresholds are lower and
interactions with other cardiovascular risk factors are
more powerful, compared with general population.
Hypertension is upto twice as common in diabetic
patients as in general population [1]. Studies have shown
that lipid abnormalities might contribute to the develop-
ment and progression of diabetic nephropathy [2]. Hyper-
cholesterolemia is a major determinant of decline of renal
function in patients with diabetes [3].
Genetic polymorphisms of the enzymes and proteins
involved in lipid metabolism like cholesteryl ester transfer
protein (CETP) and apolipoprotein E have been shown to
affect plasma lipid concentrations [4]. CETP modifies
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HDL, LDL and very low density lipoprotein (VLDL) levels.
It transfers cholesterol esters (CE) from CE rich particles
(HDL and LDL) to triglyceride rich particles (VLDL) in
exchange of triglyceride from the latter [5]. There has been
an ongoing debate as to whether CETP is pro- or anti-
atherogenic as it provides a mechanism for the transfer of
cholesterol from the cardioprotective HDL subfraction to
the potentially atherogenic LDL subfraction [6]. CETP
gene encompasses 16 exons and it has been localized on
chromosome 16q21. Several genetic polymorphisms have
been reported which may be associated with alteration in
CETP activity. TaqI B polymorphism has been most
widely studied, which results from a silent mutation in
nucleotide 277, in intron 1 of the gene. The polymor-
phism has been associated with decreased CETP mass and
an increase in HDL-cholesterol [7-9]. The TaqI polymor-
phism B1 allele of CETP has been shown to be an inde-
pendent risk factor for development of cerebral vascular
disease, in patients with T2DM [10]. The locus has also
been reported to modulate the risk for diabetic complica-
tions in patients with T2DM and effect seems to be differ-
ent between men and women [11]. Another
polymorphism D442G (Asp442-->Gly) in exon 15 of
CETP is located close to the active site of the enzyme and
leads to reduced plasma CETP mass and specific activity
[12]. The mutation is more prevalent in Japanese subjects
with high HDL-levels (>100 mg/dL) [12-14].
Apolipoprotein E (Apo E) plays a central role in clearance
of lipoprotein remnants by serving as a ligand for LDL and
apo E receptors. The gene for apo E is approximately 3.7
kb in length and contains 4 exons. It has been mapped to
chromosome 19q13 in humans. Three different APOE
alleles (ε2, ε3, and ε4) give six phenotypes. The protein
isoforms result from interchanges of cysteine and arginine
at the residue 112 and 158. In apo E2, cysteine occurs at
both positions; in apo E4 arginine is located at both posi-
tions; and in apo E3 cysteine occupies position 112 and
arginine, position 158. Based on homozygosity or hetero-
zygosity of these apo E isoproteins, a total of six pheno-
types (E2/2, E3/3, E4/4, E4/2, E4/3, and E3/2) are present
in the population [15]. APOE gene polymorphism has
been shown to be associated with the development of dia-
betic nephropathy in T2DM patients in Taiwan [2]. Apo
ε4 allele may speed up the rate of decline of glomerular fil-
tration rate (GFR) in patients with progressive diabetic
renal disease [16]. Studies have shown ε2 as positive and
ε4 as negative factor for the progression of diabetic neph-
ropathy [17,18].
Genetic epidemiologic studies, familial aggregation,
familial transmission pattern, and twin concordance rates
suggest the importance of genetic susceptibility underly-
ing the development of T2DM. High incidence of disease
in North Indian population and lack of study exploring
the genetic basis of diabetes made us to study the associa-
tion of CETP TaqI B and D442G; and APOE HhaI poly-
morphisms with T2DM.
Methods
Subjects
The study comprised of 136 T2DM patients (mean age
46.96 ± 9.38 yr.) and 264 healthy individuals (mean age
47.39 ± 16.64 yr.). Patients were enrolled from the outpa-
tients attending the clinics of Sanjay Gandhi Postgraduate
Institute of Medical Sciences from November 2003 to
April 2004. Most patients belonged to State of Uttar
Pradesh in North India. Subjects were classified as dia-
betic if they had fasting glucose concentrations ≥126 mg/
dL or 2-hour glucose concentrations ≥200 mg/dL after a
75-g oral glucose tolerance test [19,20]. These patients
were further classified according to their complication
into groups – neuropathy, nephropathy, retinopathy,
hypertension, and T2DM without complication, after
reviewing their medical chart. Neuropathy was defined as
presence of distal sensory loss in feet. Nephropathy was
defined as presence of gross albumin in urine >300 mg/d
in 24 hr collection of urine sample. Retinopathy was
defined as presence of retinal vascular microaneurysm,
blot hemorrhages, or cotton wool spots. Hypertension
was defined as presence of blood pressure of ≥140/90 mm
Hg at three different readings on different days. None of
the patients were on lipid lowering therapy at the time of
drawing their sample. All the patients were on oral
hypoglycemic agent Glimepride or Metformin or both.
The controls were the healthy staff members of institute
with negative oral glucose tolerance test. Only those
patients and controls were included who did not have the
history of coronary artery disease, neoplasia, or other met-
abolic disorder.
Study was approved from the ethical committee of the
institute. After an informed consent an overnight fasting
blood sample was taken in EDTA for analysis of lipids and
DNA. The plasma was separated by centrifugation at 3000
rpm within 10 minutes of blood collection for the lipid
analysis. The genomic DNA was extracted from peripheral
blood leucocytes pellet using the standard salting out
method [21].
Lipids levels
In plasma, total cholesterol, triglyceride, and HDL-choles-
terol were analyzed using commercially available kits
(Accurex Biomedical Pvt. Ltd., Mumbai, India). For HDL-
cholesterol estimation, selective precipitation of other
lipoproteins was done using sodium tungstate and mag-
nesium chloride. LDL-cholesterol was calculated accord-
ing to previously described method [22].BMC Endocrine Disorders 2005, 5:7 http://www.biomedcentral.com/1472-6823/5/7
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Genotyping
CETP TaqI B and D442G polymorphisms
A fragment of 535 bp in intron 1 of the CETP gene was
amplified by polymerase chain reaction (PCR) in a DNA
thermal cycler (DNA Engine PTC-100, MJ Research, Inc)
using primers forward 5'-CACTAGCCCAGAGAGA-
GGAGTGCC-3' and, reverse 5'-CTGAGCCCAGCCG-
CACACTAAC-3' [23]. For D442G polymorphism analysis
primers used to amplify exon 15 and flanking sequences
were as follows: forward 5'-GTGTTTACAGCCCTCAT-
GAAC-3' and reverse 5'-AAGCCAAAGTCCATCTCTGCAG-
3' [24]. Each amplification was performed using 200 ng of
genomic DNA in a volume of 25 µl using 12.5 pmol of
each primer, 200 µM each dNTPs, 15 mM MgCl2, 100 mM
Tris and two units of Taq polymerase (Bangalore Genei,
Bangalore). DNA templates were initially denatured at
95°C for three minutes, followed by 30 cycles with dena-
turation at 95°C for 30 seconds, annealing at 60°C for 30
seconds and, extension at 72°C for 45 seconds and
finally, an extension at 72°C for five minutes. The PCR
products were subjected to restriction digestion with 4 U
of the restriction endonuclease TaqI for 15 µl of PCR sam-
ple at 65°C for three hours in the buffer recommended by
the manufacturer (MBI Fermentas, USA).
TaqI B genotype was determined by electrophoresis of
restricted PCR product on 2% agarose gel followed by
ethidium bromide staining. Presence of TaqI site (B1
allele) gave two bands of 174 bp and 361 bp and absence
(B2 allele) showed one band of 535 bp.
For genotyping of D442G polymorphism, TaqI digested
PCR products were run on 20% polyacrylamide gel. This
product has two sites for TaqI. Homozygous subjects with
DD give two bands (218 bp and 69 bp) and heterozygous
show four bands (218 bp, 69 bp, 41 bp and 28 bp) and
homozygous for G allele show three bands (218 bp, 41
bp, and 28 bp).
APOE polymorphism
The primers used to analyze the APOE were as follows:
Forward 5'-ACAGAATTCGCCCCGGCCTGGTACAC-3'
and Reverse 5' TAAGCTTGGCACGGCTGTCCAAGG A-3'
[25]. The PCR products were initially denatured at 95°C
for five minute, cycling conditions were 95°C for one
minute, 58°C for one minute, 70°C for one minute (30
cycles) followed by final extension at 72°C for 10 min-
utes. After PCR amplification, 10 units of HhaI were added
for digestion (>3 h at 37°C). The digested product was
run on 20% polyacrylamide gel at 300 V, stained with
ethidium bromide and visualized under ultraviolet light.
Statistical evaluation
Data was analyzed using the statistical software (SPSS
vs.11.5). Direct gene counting method was used to deter-
mine the frequency of genotypes and alleles. The chi-
square test or Fisher's exact test was used to determine dif-
ferences in frequencies. P-value < 0.05 was considered as
significant. All continuous variables were expressed as
mean ± SD. The normality in the distribution of total-cho-
lesterol, HDL-cholesterol, triglyceride and LDL-choles-
terol was confirmed by using normal probability plots.
Since total-cholesterol, HDL-cholesterol, triglyceride and
LDL-cholesterol were not distributed normally they were
naturally log transformed. Significant covariates for each
dependent trait were identified using Pearson's correla-
tion with 5% level of significance. Sex and BMI were
found to be significant covariates for total cholesterol, sex
for triglyceride and HDL-cholesterol, and BMI for LDL-
cholesterol. Total cholesterol, triglyceride, HDL-choles-
terol, and LDL-cholesterol values were subjected to a lin-
ear regression procedure to obtain adjusted values for
significant covariates. ANOVA was performed to deter-
mine genetic source of variation for biochemical traits in
control population separately. Lipid variables were taken
as dependent variable and the genetic marker as inde-
pendent. If this test was significant, Tukey posthoc test
was performed to find out which genotype/allele differed
significantly from others. All calculations were done in
total samples as well as in males and females separately
Results
Table 1 and table 2 show the demographic and lipid pro-
file of study population respectively. Plasma concentra-
tions of total-cholesterol (p = 0.001) and LDL-cholesterol
(p = 0.00008) levels were significantly higher in T2DM
patients than in controls but HDL-cholesterol and triglyc-
eride levels were not significantly different (Table 2 –
unadjusted values). After stratification of population on
the basis of gender same pattern of lipid profile was
found. Overall, males had lower circulating levels than
females in patients as well as in controls.
CETP TaqI B polymorphism
In controls the frequency of B1 and B2 alleles of CETP
TaqI B gene was 52.65% and 47.35% respectively, which
is similar to most of Caucasian populations. The observed
genotypes B1B1, B1B2, and B2B2 were in Hardy Weinberg
equilibrium. Analysis of the polymorphism showed that
the frequency of B2 allele and B2B2 genotype was not sig-
nificantly different in patients and controls (43.75% vs
47.35% and 16.91% vs 21.97%, Table 3). Further stratifi-
cation of data according to gender (Table 4) did not show
any association with the disease. After subdividing study
population into different age groups no significant associ-
ation was found but B1B2 genotype showed weak associ-
ation and risk (p = 0.054; OR 3.826, 95% CI 0.916–15.98)
for disease in 61–75 age group (Table 5).BMC Endocrine Disorders 2005, 5:7 http://www.biomedcentral.com/1472-6823/5/7
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When patient population was sub-divided according to
the associated complications viz., neuropathy, nephropa-
thy, retinopathy, hypertension, and no complication,
B1B2 genotype was significantly (p = 0.018) associated
with high risk of hypertension in diabetic patients (OR =
3.068, 95% CI 1.183–7.958), and B1B1 was found to be
significantly protective (p = 0.038, OR = 0.139, 95% CI
0.018–1.093) for hypertension (Table 6).
CETP D442G polymorphism
For D442G no polymorphism was found in patient or
control population, only D allele was present (Table 3).
APOE HhaI polymorphism
Frequencies of all APOE genotypes were not significantly
different between the diabetic and control group in total
or after stratifying according to gender or age (Table 7).
Table 1: Demographic profile of T2DM patients and controls
Patient Control
Total Male Female Total Male Female
Age (year) 46.96 ± 9.38 48.17 ± 10.09 45.32 ± 8.13 47.37 ± 16.66 50.76 ± 19.81 44.71 ± 13.15
Height (cm) 160.33 ± 7.74 164.20 ± 6.80 153.43 ± 3.19 161.21 ± 6.65 166.29 ± 6.47 157.57 ± 3.82
Weight (kg) 62.75 ± 12.11 64.83 ± 11.76 59.04 ± 12.08 60.86 ± 9.26 64.76 ± 9.64 57.98 ± 7.90
BMI (kg/m2) 24.37 ± 4.21 23.98 ± 3.73 25.07 ± 4.97 23.34 ± 2.68 23.41 ± 2.81 23.29 ± 2.61
Values in mean ± SD
Table 2: Total cholesterol, triglyceride, HDL-cholesterol and LDL-cholesterol concentrations in T2DM patients and controls
Patients# Control#
Total (n = 83) Male (n = 48) Female (n = 35) Total (n = 135) Male (n = 87) Female (n = 48)
Total-Cholesterol*◆  (mg/dl) 187.24 (53.43) 179.13 (53.18) 198.37 (52.49) 150.22 (41.18) 143.42 (28.24) 162.44 (56.02)
Triglyceride* (mg/dl) 186.52 (92.22) 172.52 (87.09) 205.71 (96.81) 145.67 (50.56) 138.50 (41.43) 158.68 (62.29)
HDL Cholesterol* (mg/dl) 39.61 (6.54) 37.63 (5.97) 42.34 (6.36) 38.79 (6.77) 38.05 (6.99) 40.12 (6.19)
LDL-cholesterol*◆  (mg/dl) 110.32 (46.84) 107.00 (47.46) 114.89 (46.25) 82.30 (38.58) 77.72 (26.42) 90.59 (53.45)
Values: (mean ± SD)
# Lipid profile was available in 83 T2DM patients and 135 controls
* Unadjusted values have been shown
◆  Significant value
Table 3: CETP TaqI B and D442G polymorphisms: allele and genotype frequencies in T2DM patients and controls
Patient* n (%) Control* n (%) P-value OR (95% CI)
B1B1 40 (29.41) 72 (27.27) 0.652 1.11 (0.70–1.76)
B1B2 73 (53.68) 134 (50.76) 0.580 1.12 (0.74–1.70)
B2B2 23 (16.91) 58 (21.97) 0.233 0.72 (0.42–1.23)
B1 153 (56.25) 278 (52.65) 0.333 1.16 (0.86–1.55)
B2 119 (43.75) 250 (47.35) 0.333 0.87 (0.64–1.16)
DD 136 (100) 264 (100) - -
GG 0 (0) 0 (0) - -
* Total T2DM patients 136 and controls 264BMC Endocrine Disorders 2005, 5:7 http://www.biomedcentral.com/1472-6823/5/7
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Genetic polymorphisms and lipid profile
In diabetic patients having neuropathy significantly dif-
ferent levels of total cholesterol (p = 0.001) and LDL-cho-
lesterol (p = 0.001) were found than in T2DM only
patients. Unadjusted values were higher in T2DM patients
with neuropathy than in patients with T2DM only (total-
cholesterol, 225.89 ± 45.18 mg/dL vs. 186.45 ± 51.56 mg/
dL and LDL-cholesterol, 152.33 ± 41.07 mg/dL vs. 105.72
± 44.09 mg/dL respectively) but adjusted values were
higher in patients with T2DM only than in patients with
T2DM and neuropathy (total-cholesterol, 5.09 ± 0.07 vs.
5.00 ± 0.06 mg/dL and LDL-cholesterol, 4.45 ± 0.09 vs.
4.32 ± 0.11 mg/dL respectively). In T2DM patients with
retinopathy adjusted total-cholesterol and LDL-choles-
terol levels were significantly (p = 0.029 and p = 0.001
respectively) lower (5.00 ± 0.10 vs. 5.09 ± 0.07 mg/dL and
4.29 ± 0.11 vs. 4.45 ± 0.09 mg/dL respectively) than
patients with T2DM only.
Lipid profile analysis did not show any significant differ-
ence in distribution among genotypes of CETP TaqI B pol-
ymorphism or APOE HhaI polymorphism. In T2DM
patients though the levels of total-cholesterol and triglyc-
eride were higher in ε4 allele carriers than in ε2 or ε3 allele
carriers, but the difference was not statistically significant
(Table 8).
Discussion
To our knowledge, this is the first study of its kind in
North Indian population. We studied association of CETP
TaqI B, CETP D442G, and APOE Hha I polymorphisms
with T2DM and with complications associated with the
disease. In the present study, no association of CETP TaqI
B polymorphism with the disease was found but B1B2
genotype was risk factor for hypertension along with
diabetes (P = 0.028). However, B1B1 was found to be pro-
tective (P = 0.038).
Table 4: Allele and genotype frequencies of CETP TaqI B polymorphism in T2DM patients and controls after stratifying in male and 
female
Male* Female*
Patient n (%) Control n (%) P-value OR (95% CI) Patient n (%) Control n (%) P-value OR (95% CI)
B1B1 22 (27.8) 34 (29.3) 0.825 0.93 (0.49–1.76) 18 (31.6) 38 (25.7) 0.395 1.34 (0.68–2.61)
B1B2 44 (55.7) 60 (51.7) 0.585 1.17 (0.66–2.08) 29 (50.9) 74 (50.0) 0.910 1.04 (0.56–1.91)
B2B2 13 (16.5) 22 (19.0) 0.654 0.84 (0.40–1.79) 10 (17.5) 36 (24.3) 0.297 0.66 (0.30–1.44)
B1 88 (55.70) 128 (55.17) 0.920 1.02 (0.68–1.53) 65 (57.02) 150 (50.68) 0.249 1.29 (0.84–2.00)
B2 70 (44.30) 104 (44.83) 0.920 0.98 (0.65–1.47) 49 (42.98) 146 (49.32) 0.249 0.77 (0.50–1.20)
* Total male patients 79, controls 116 and total female patients 57, controls 148
Table 5: CETP TaqI B frequencies in T2DM patients and controls after subdividing according to age
GENOTYPE AGE (YEAR)
(PATIENT NO./CONTROL 
NO.)
P-VALUE OR (95% CI)
B1B1 Upto 30 (2/12) 0.599 2.000 (0.298–13.435)
31–45 (15/23) 0.836 0.923 (0.430–1.980)
46–60 (21/18) 0.186 1.650 (0.783–3.479)
Above 60 (2/19) 0.481 0.433 (0.085–2.206)
B1B2 Upto 30 (3/28) 1.000 1.071 (0.164–7.014)
31–45 (34/41) 0.243 1.508 (0.756–3.009)
46–60 (27/40) 0.288 0.694 (0.354–1.363)
Above 60 (8/23) 0.054 3.826 (0.916–15.984)
B2B2 Upto 30 (0/8) 1.000 -
31–45 (7/17) 0.199 0.538 (0.207–1.398)
46–60 (14/18) 0.879 0.940 (0.424–2.084)
Above 60 (1/14) 0.433 0.300 (0.035–2.557)BMC Endocrine Disorders 2005, 5:7 http://www.biomedcentral.com/1472-6823/5/7
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CETP is a key regulator of lipid metabolism and polymor-
phism of the gene may be associated with complications
of diabetes mellitus. B1B1 carriers have been reported to
show lowest and B2B2 carriers highest HDL-cholesterol
concentration [26-31]. but no association of TaqI B poly-
morphism was found in several other studies [32-34] A
recent study in Singapore population comprising Chi-
nese, Malays, and Asian Indians also showed that B2 allele
was associated with high HDL-cholesterol concentration.
Inspite of highest frequency of B2 allele, the HDL-choles-
terol levels were lower in Asian Indians than in Chinese
and Malays [35].
We found that B1B1 is protective for diabetes associated
hypertension which seems contradictory to reports relat-
ing B1B1 with low HDL-cholesterol and B2B2 with high
HDL-cholesterol. Relvas et al. [36] also found a higher
prevalence of the B2B2 genotype of the CETP gene among
diabetics than that observed in non-diabetics. These con-
tradictory results indicate towards two possibilities.
Firstly, TaqI B polymorphism is not the only determinant
of HDL-cholesterol level, other polymorphisms or muta-
tion in the CETP are more potent determinant. Various
mutations/polymorphisms resulting in amino acid substi-
tutions, namely A373P, I405V and R451Q, have been
Table 6: TaqI B CETP genotypes in various complications of T2DM
CLINICAL COMPLICATION 
(NO. OF PATIENTS)
GENOTYPE (T2DM 
PATIENT NO. WITH 
COMPLICATION/
WITHOUT 
COMPLICATION)
P-VALUE OR (95% CI)
Nephropathy (29) B1B1 (8/24) 0.891 0.937 (0.365–2.403)
B1B2 (15/42) 0.917 1.046 (0.449–2.437)
B2B2 (6/17) 0.981 1.013(0.356–2.879)
Neuropathy (12) B1B1 (4/24) 0.744 1.229 (0.338–4.468)
B1B2 (5/42) 0.563 0.697 (0.205–2.375)
B2B2 (3/17) 0.712 1.294 (0.316–5.307)
Retinopathy (9) B1B1 (3/24) 0.719 1.229 (0.284–5.319)
B1B2 (4/42) 1.000 0.781 (0.196–3.115)
B2B2(2/17) 1.000 1.109 (0.211–5.830)
Hypertension (29) B1B1 (1/17) 0.038 0.139 (0.018–1.093)
B1B2 (22/42) 0.018 3.068 (1.183–7.958)
B2B2 (6/24) 0.389 0.641 (0.232–1.772)
Table 7: Apolipoprotein E gene polymorphism genotype and allele frequencies in T2DM patients and controls
Total# Male# Female#
Patient n (%) Control n (%) Patient n (%) Control n (%) Patient n (%) Control n (%)
E2E2* 1 (0.7) 0 (0) 1 (1.3) 0 (0) 0 (0) 0 (0)
E3E3* 101 (74.3) 197 (74.6) 55 (69.6) 88 (75.9) 46 (80.7) 109 (73.6)
E4E4* 1 (0.7) 1 (0.4) 1 (1.3) 0 (0) 0 (0) 1 (0.7)
E2E3* 11 (8.1) 19 (7.2) 8 (10.1) 9 (7.8) 3 (5.3) 10 (6.8)
E2E4* 4  ( 2 . 9 )6  ( 2 . 3 )2  ( 2 . 5 )5  (4.3) 2 (3.5) 1 (0.7)
E3E4* 18 (13.2) 41 (15.5) 12 (15.2) 14 (12.1) 6 (10.5) 27 (18.2)
E2* 17 (6.3) 25 (4.7) 12 (7.59) 14 (6.03) 5 (4.39) 11 (3.72)
E3* 231 (84.9) 454 (86.0) 130 (82.28) 199 (85.78) 101 (88.60) 255 (86.15)
E4* 24 (8.8) 49 (9.3) 16 (10.13) 19 (8.19) 8 (7.02) 30 (10.14)
*No significant difference between patients and controls
# Total patients 136, 79 male and 57 female; and total controls 264, 116 male and 148 femaleBMC Endocrine Disorders 2005, 5:7 http://www.biomedcentral.com/1472-6823/5/7
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found to be independent variations from the TaqI B poly-
morphism effecting HDL-cholesterol and CETP activity
[27,33,37-39]. Secondly, actual gene responsible/protec-
tive for hypertension may be different which is in linkage
disequilibrium with CETP TaqI B polymorphism. Klerkx
et al. [5] also showed that the TaqI B polymorphism is not
instrumental in determining CETP or HDL-C levels, but is
a marker for the -629 promoter variant.
D442G polymorphism has been implicated in alteration
of CETP activity. The D442G acts in dominant negative
manner with severe effect in heterozygous state [14]. A
high prevalence of two different CETP  gene mutations
(D442G, 5.1%; intron 14G:A, 0.5%), was found in men of
Japanese ancestry in the Honolulu Heart Program and
mutations were associated with decreased CETP (-35%)
and increased HDL-cholesterol levels (+10% for D442G)
[40]. In our population exonic mutation D442G of CETP
gene was not observed. In other populations of the world
frequency of D442G varies greatly [41,42], in some it is
not even polymorphic [43] (Table 9). In Japan, D442G
mutation in CETP gene is around 7% in random male
samples [44]. Frequency of the D442G substitution in
Chinese showed enormous variations (0.2%–5%) [45-
48] which may be due to ethnic differences in the studied
populations. Absence of D442G polymorphism shows
similarity of our population with Caucasians.
Earlier studies in T2DM patients have shown that ε2 and
ε4 alleles of APOE are associated with high risk for dyslip-
idemia, nephropathy, retinopathy, and coronary artery
disease [18,49-51] but other studies have shown
contradictory results. Powell et al. [52] showed that APOE
gene polymorphism is not linked to amyloid formation or
progression of islet dysfunction in T2DM. No significant
difference was found in APOE  genotype frequencies
between hypertriglyceridemic and normotriglyceridemic
among T2DM patients [53]. Study in San Luis Valley,
Colorado also showed, no significant effect of the APOE
polymorphism on cholesterol levels among diabetics
[54]. Another study in individuals with family history of
diabetes showed that APOE  polymorphism is not
associated with lipids in men or women [55]. A previous
study from Mumbai, India showed that APOE phenotype
frequencies were not different between diabetic patients
and healthy controls [56]. Our study also supports no
association of APOE HhaI polymorphism with either
T2DM or lipid variation. However molecular mechanism
leading to lipid variation is not fully clear and various
gene-gene and gene-environment interactions have also
been observed, suggesting complex mechanisms leading
to complications in T2DM patients.
Although our study found abnormal lipid profile in dia-
betes patients and its association with complications like
diabetic neuropathy and retinopathy, yet these lipid pro-
file abnormalities did not correlate with CETP TaqI B or
Table 8: Lipid profile stratified according to APOE alleles
Patient/Control Lipid profile ε2 ε3 ε4
Patients Total-cholesterol (mg/dl) 191.33 ± 60.98 185.69 ± 53.14 200.50 ± 51.47
HDL-cholesterol (mg/dl) 38.44 ± 6.56 39.70 ± 6.60 39.50 ± 6.00
Triglyceride (mg/dl) 143.22 ± 75.65 189.57 ± 93.10 183.14 ± 87.58
LDL-cholesterol (mg/dl) 124.24 ± 48.92 108.07 ± 46.94 124.37 ± 41.61
Controls Total-cholesterol (mg/dl) 172.55 ± 65.76 148.85 ± 39.45 147.28 ± 28.83
HDL-cholesterol (mg/dl) 40.07 ± 5.19 38.73 ± 6.82 38.38 ± 7.26
Triglyceride (mg/dl) 130.97 ± 32.69 145.93 ± 51.77 154.71 ± 46.61
LDL-cholesterol (mg/dl) 106.29 ± 63.21 80.93 ± 36.58 77.96 ± 27.46
* Unadjusted values
Table 9: Allele frequencies of CETP D442G polymorphism in 
various populations
Population D (%) G (%) Reference
Japan 96.8 3.2 24
Japan 94.9 5.1 40
Taiwan 97.7 2.3 57
Taiwan 95.54 4.46 58
Korea 94.7 5.3 42
Korea 9 464 1
China 99.3 0.7 48
China 9 554 7
China 96.52 3.48 46
China 97.9 2.1 45
UK 100 0 43
India 100 0 Present StudyBMC Endocrine Disorders 2005, 5:7 http://www.biomedcentral.com/1472-6823/5/7
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APOE HhaI polymorphisms. In T2DM patients with
neuropathy, unadjusted values of total-cholesterol and
LDL-cholesterol were higher than, patients with T2DM
only. After adjusting for covariates, results were opposite
which shows the effect of covariates on lipid variation.
The absence of any association of lipid profile with
genetic subgroups suggest involvement of other environ-
mental and genetic factors in the regulation of circulating
lipid levels as well as the complex mechanism of T2DM.
Conclusion
CETP TaqI B and APOE HhaI polymorphism may not be
associated with type II diabetes mellitus in north Indian
population, however CETP TaqI B polymorphism may be
associated with certain complications along with T2DM.
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